https://mindmedicinelaw.com/briefing/systematic-review-reveals-major-gaps-in-pap-implementation-research-20261102-56182The Psychedelic Journalen2026-11-03T22:06:41.129390+00:00Systematic Review Reveals Major Gaps in PAP Implementation Researchpsychedelic-assisted psychotherapy, implementation science, systematic review, clinical practice, mental health policy, regulatory compliance, public health, training models, access barriershttps://mindmedicinelaw.com/briefing/blood-pressure-risks-of-ketamine-esketamine-in-depression-systematic-review-prot-20261102-56227The Psychedelic Journalen2026-11-03T22:06:22.835591+00:00Blood Pressure Risks of Ketamine/Esketamine in Depression: Systematic Review Protocol (Global, 2026)ketamine, esketamine, blood pressure, hypertension risk, systematic review, depression treatment, clinical trials, regulatory guidance, cardiovascular safetyhttps://mindmedicinelaw.com/briefing/spontaneous-neuropathic-pain-mechanisms-and-clinical-implications-20261102-55963The Psychedelic Journalen2026-11-02T22:07:04.052152+00:00Spontaneous Neuropathic Pain: Mechanisms and Clinical Implicationsspontaneous neuropathic pain, pain mechanisms, clinical trial endpoints, psychedelic research, biomarker phenotyping, chronic pain, precision medicine, regulatory policy, pain diagnosticshttps://mindmedicinelaw.com/briefing/childhood-trauma-linked-to-lower-cb1-receptor-availability-pet-study-insights-20261031-55918The Psychedelic Journalen2026-11-02T22:07:20.229245+00:00Childhood Trauma Linked to Lower CB1 Receptor Availability: PET Study Insightscb1 receptor, childhood trauma, endocannabinoid system, pet imaging, psychedelic therapy, cannabinoid therapy, biomarkers, clinical trial design, neurobiology of traumahttps://mindmedicinelaw.com/briefing/spiritual-experiences-in-interoceptive-training-for-moud-clinical-implications-20261029-56222The Psychedelic Journalen2026-11-03T22:07:12.709479+00:00Spiritual Experiences in Interoceptive Training for MOUD: Clinical Implicationsinteroceptive awareness, spiritual experience, opioid use disorder, MOUD, mindful awareness in body-oriented therapy, substance use disorder, psychedelic-assisted therapy, adjunctive therapies, clinical researchhttps://mindmedicinelaw.com/briefing/ketamine-s-neuroprotection-in-parkinson-s-models-bdnf-independence-20261029-56233The Psychedelic Journalen2026-11-03T22:06:55.459219+00:00Ketamine’s Neuroprotection in Parkinson’s Models: BDNF Independenceketamine, parkinson's disease, neuroprotection, bdnf, trkB signaling, preclinical research, rodent models, mechanisms of action, clinical translation, neurodegenerative diseasehttps://mindmedicinelaw.com/briefing/topical-ketamine-for-oral-mucositis-pain-evidence-and-gaps-in-oncology-supportiv-20261027-55978The Psychedelic Journalen2026-11-02T22:06:27.319413+00:00Topical Ketamine for Oral Mucositis Pain: Evidence and Gaps in Oncology Supportive Caretopical ketamine, oral mucositis, cancer pain management, supportive care, opioid-sparing, clinical trials, oncology, compounding pharmacy, regulatory approval, ketamine safetyhttps://mindmedicinelaw.com/briefing/sex-differences-in-psilocybin-vs-escitalopram-for-depression-2026-bayesian-reana-20261026-55935The Psychedelic Journalen2026-11-02T22:06:49.185755+00:00Sex Differences in Psilocybin vs Escitalopram for Depression: 2026 Bayesian Reanalysispsilocybin, escitalopram, major depressive disorder, sex differences, clinical trial design, bayesian analysis, psychedelic research, hormonal factors, regulatory implications